home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 09/12/22

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmona...
KROS - Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmona...

KROS - Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting

LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmona...

KROS - Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Keros Therapeutics press release ( NASDAQ: KROS ): Q2 GAAP EPS of -$1.13 misses by $0.07 . Cash and cash equivalents OF $215.62M For further details see: Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

KROS - Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high transfusion burden patients achieved transfusion independence KER-012 preliminary ...

KROS - Keros Therapeutics (KROS) Investor Presentation - Slideshow

The following slide deck was published by Keros Therapeutics, Inc. in conjunction with this event. For further details see: Keros Therapeutics (KROS) Investor Presentation - Slideshow

KROS - Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
KROS - Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time. LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-...

KROS - Keros potential drug for high blood pressure in lungs KER-012 shows tolerability in healthy people in interim data

Keros Therapeutics (NASDAQ:KROS) said preliminary data from part 1 of its phase 1 trial of KER-012 in healthy postmenopausal volunteers showed that the drug was well tolerated. Lexington, Mass.-based Keros is exploring KER-012 as a treatment for pulmonary arterial hypertension ...

KROS - Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

LEXINGTON, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscul...
Previous 10 Next 10